$MAIA: An $80M Phase 3 oncology company with 17.8-month survival data, heavy insider buying, and partnerships with Regeneron, Roche and BeOne
I have been searching for small oncology companies with the potential to experience the kind of revaluation that occurs when convincing clinical data finally attracts market attention. **MAIA Biotechnology ($MAIA)** may be one of the more interesting examples I have …